Orly Vardeny et al. JCHF 2014;2:

Slides:

Advertisements

Similar presentations

Entresto® (sacubitril & valsartan)

Advertisements

Vasoactive peptides By S.Bohlooli, PhD. Vasoactive peptides Vasoconstrictors: Angiotensin II Vasopressin Endothelins Neuropeptide Y urotensin Vasodilators:

PARADIGM-HF Study Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure A multicenter, randomized,

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Path to an Angiotensin Receptor Antagonist-Neprilysin.

Disclosure Statement Philip Leong Potential conflicts of interest: none Sponsorship: none Speaker’s presentation is educational in nature and indicates.

Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Role of the Natriuretic Peptide System in Cardiorenal.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pro–Atrial Natriuretic Peptide: A Novel Guanylyl.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin II type 1 receptor antagonist decreases.

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Mariell.

No conflicts of interest decleared

The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.

Renin-angiotensin-aldosterone and potassium-aldosterone feedback loops

Figure 1 Mechanisms of action of novel therapeutics for heart failure

An Emerging Role of Natriuretic Peptides

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Stephen W. Waldo et al. JACC 2008;51:

Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.

Cardiac Biomarkers.

Biomarkers in Heart Failure

Median NT-proBNP levels (pg/mL) by GFR and 60-day survival

Diabetes Mellitus and Heart Failure

Clyde W. Yancy et al. JACC 2017;70:

Clyde W. Yancy et al. JACC 2017;70:

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Volume 82, Issue 1, Pages 7-8 (July 2012)

Changes in plasma Ald, Ang II and ANP concentrations before and after 4-day head-down bed rest (HDBR) in both the control (Con) and transcutaneous electrical.

Giovanni Davogustto, MD, Thomas J. Wang, MD, Deepak K. Gupta, MD

Viper venom for diabetic nephropathy

Eugene Braunwald JCHF 2013;1:1-20

Stavros V. Konstantinides et al. JACC 2016;67:

Antoni Bayés-Genís JCHF 2015;3:

Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes

G. Michael Felker et al. JCHF 2014;2:

Editorial Heart Failure Clinics

Viper venom for diabetic nephropathy

Sexual Activity and Chronic Heart Failure

Renoprotective effects of vitamin D analogs

Fig. 2. Evidence-based medication prescriptions

Wayne L. Miller et al. JCHF 2013;1:

Jordan B. King et al. JCHF 2016;4:

G. Michael Felker et al. JCHF 2014;2:

Svend A. Mortensen et al. JCHF 2014;2:

An Emerging Role of Natriuretic Peptides

Thomas Quaschning, Jan Galle, Christoph Wanner

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Peter E. Carson et al. JCHF 2015;3:

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Rami Doukky et al. JCHF 2016;4:24-35

Receiver operating characteristics curve of N-terminal pro-atrial natriuretic peptide plasma levels (dark line) and brain natriuretic peptide (dashed line)

Maria Rosa Costanzo et al. JCHF 2016;4:95-105

Paul M. McKie, BS, John C. Burnett, MD Mayo Clinic Proceedings

When we compared cardiac volumes (ED and ES) between those with high BNP levels (BNP >400 pg/mL) and low BNP (

Jordan B. King et al. JCHF 2016;4:

Svend A. Mortensen et al. JCHF 2014;2:

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for patients undergoing surgical aortic valve replacement (SAVR) (A), patients undergoing.

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Dennis M. McNamara et al. JCHF 2014;2:

Zeenat Safdar et al. JCHF 2014;2:

Orly Vardeny et al. JCHF 2016;4:

Associations of peripartum biomarker levels with e' at 1 month postpartum (PP2). Associations of peripartum biomarker levels with e' at 1 month postpartum.

Schematic of the interaction between the renin-angiotensin-aldosterone system (RAAS) system and the natriuretic peptides and how the RAAS modulators and.

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

Spearman’s rank correlation between preoperative serum levels of BNP/NT-proBNP and expression of HIF-2 alpha and preoperative serum level of VEGF. There.

Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration and 3 months of therapy: full analysis.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Receiver operating curves assessing the prognostic accuracy of a) N-terminal pro-brain natriuretic peptide, b) pro-atrial natriuretic peptide, c) high-sensitivity.

Overall survival in all cases.

Presentation transcript:

Orly Vardeny et al. JCHF 2014;2:663-670 Schematic Showing the Mechanism of Action of LCZ696 Heart failure stimulates both the renin-angiotensin system and the natriuretic peptide system. LCZ696 is composed of 2 molecular moieties, the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril (AHU377). Valsartan blocks the angiotensin type I (AT1) receptor. Sacubitril is converted enzymatically to the active neprilysin inhibitor LBQ657, which inhibits neprilysin, an enzyme that breaks down the breakdown of atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), as well as other vasoactive substances. N-terminal pro-BNP (NT-proBNP) is not a substrate for neprilysin. Orly Vardeny et al. JCHF 2014;2:663-670 American College of Cardiology Foundation